Bullous Pemphigoid

  • Panagiotis G. StavropoulosEmail author
  • Eleni Remoudaki


Bullous pemphigoid (BP) is an acquired, subepidermal autoimmune blistering disease. Urticarial and figured erythemas are common prodromal eruptions, and subsequently, large tense blisters arise with a base of normal or erythematous skin. Diagnosis is made by biopsy and direct and indirect immunofluorescence. Topical steroids should be considered first-line treatment in localized or moderate BP, and systemic corticosteroids are rapidly inducing remission in the majority of patients. Other immunosuppressive agents used, among others, are azathioprine, cyclophosphamide, chlorambucil, and mycophenolate mofetil.


Bullous pemphigoid Autoimmune blistering disease Corticosteroids Immunosuppressive agents 

Further Reading

  1. Bastuji-Garin S, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol. 2011;131:637–43.CrossRefGoogle Scholar
  2. Bouscrarat F, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty six cases. J Am Acad Dermatol. 1996;34:683–7.CrossRefGoogle Scholar
  3. Du-Thanh A, et al. Combined treatment with low-dose methotrexate and initial short- term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165:1337–43.CrossRefGoogle Scholar
  4. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid. J Am Acad Dermatol. 2001;44:83–8.CrossRefGoogle Scholar
  5. Hideyuki U, Akihiko S, et al. What’s new in bullous pemphigoid. J Dermatol. 2010;37:194–204.CrossRefGoogle Scholar
  6. Huilgol SC, Black MM. Management of immunobullous diseases. I. Pemphigoid. Clin Exp Dermatol. 1995;20:189–201.CrossRefGoogle Scholar
  7. Kolbach DN, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 1995;133:88–92.CrossRefGoogle Scholar
  8. Orvis AK, et al. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183–99.CrossRefGoogle Scholar
  9. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP 180 correlates with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8.CrossRefGoogle Scholar
  10. Tee S, Yosipovitch G, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo- controlled study. Arch Dermatol. 2012;148:307–14.CrossRefGoogle Scholar
  11. Venning VA, et al. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167:1200–14.CrossRefGoogle Scholar
  12. Yancey KB, Egan CA. Pemphigoid. Clinical, histology, immunopathology, and therapeutic considerations. JAMA. 2000;284(3):350–6.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.1st Department of DermatologyA. Syggros Hospital, University of Athens Medical SchoolAthensGreece
  2. 2.1st Department of DermatologyA. Syggros HospitalAthensGreece

Personalised recommendations